Open AccessP1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
Author(s) -
Saraf S.,
Brown R. C.,
Hagar R. W.,
Idowu M.,
Osunkwo I.,
Kalfa T. A.,
Kuypers F. A.,
Geib J.,
Schroeder P.,
Wu E.,
Kelly P.,
Telen M. J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000848836.01685.87
Subject(s) - medicine , adverse effect , discontinuation , acute chest syndrome , pharmacodynamics , cohort , deep vein , gastroenterology , thrombosis , sickle cell anemia , pharmacokinetics , disease